Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso
Objectives: The World Health Organization pre-qualified single-dose typhoid conjugate vaccine (TCV) and requested data on co-administration with routine vaccines. The co-administration of Typbar TCV (Bharat Biotech International) with routine group A meningococcal conjugate vaccine (MCV-A) and measl...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-01-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971220323092 |
| _version_ | 1818921331051200512 |
|---|---|
| author | Sodiomon B. Sirima Alphonse Ouedraogo Nouhoun Barry Mohamadou Siribie Alfred B. Tiono Issa Nébié Amadou T. Konaté Gloria Damoaliga Berges Amidou Diarra Moussa Ouedraogo Issiaka Soulama Alimatou Hema Shrimati Datta Yuanyuan Liang Elizabeth T. Rotrosen J. Kathleen Tracy Leslie P. Jamka Kathleen M. Neuzil Matthew B. Laurens |
| author_facet | Sodiomon B. Sirima Alphonse Ouedraogo Nouhoun Barry Mohamadou Siribie Alfred B. Tiono Issa Nébié Amadou T. Konaté Gloria Damoaliga Berges Amidou Diarra Moussa Ouedraogo Issiaka Soulama Alimatou Hema Shrimati Datta Yuanyuan Liang Elizabeth T. Rotrosen J. Kathleen Tracy Leslie P. Jamka Kathleen M. Neuzil Matthew B. Laurens |
| author_sort | Sodiomon B. Sirima |
| collection | DOAJ |
| description | Objectives: The World Health Organization pre-qualified single-dose typhoid conjugate vaccine (TCV) and requested data on co-administration with routine vaccines. The co-administration of Typbar TCV (Bharat Biotech International) with routine group A meningococcal conjugate vaccine (MCV-A) and measles–rubella (MR) vaccine was tested. Methods: This was a double-blind, randomized controlled trial performed in Ouagadougou, Burkina Faso. Children were recruited at the 15-month vaccination visit and were assigned randomly (1:1:1) to three groups. Group 1 children received TCV plus control vaccine (inactivated polio vaccine) and MCV-A 28 days later; group 2 children received TCV and MCV-A; group 3 children received MCV-A and control vaccine. Routine MR vaccine was administered to all participants. Safety was assessed at 0, 3, and 7 days after immunization, and unsolicited adverse events and serious adverse events were assessed for 28 days and 6 months after immunization, respectively. Results: A total of 150 children were recruited and vaccinated. Solicited symptoms were infrequent and similar for TCV and control recipients, as were adverse events (group 1, 61.2%; group 2, 64.0%; group 3, 68.6%) and serious adverse events (group 1, 2.0%; group 2, 8.0%; group 3, 5.9%). TCV generated robust immunity without interference with MCV-A vaccine. Conclusions: TCV can be safely co-administered at 15 months with MCV-A without interference. This novel study on the co-administration of TCV with MCV-A provides data to support large-scale uptake in sub-Saharan Africa. |
| first_indexed | 2024-12-20T01:35:56Z |
| format | Article |
| id | doaj.art-1e46ffdb2bb145e39288a48a3a9d8927 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-12-20T01:35:56Z |
| publishDate | 2021-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-1e46ffdb2bb145e39288a48a3a9d89272022-12-21T19:58:01ZengElsevierInternational Journal of Infectious Diseases1201-97122021-01-01102517523Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina FasoSodiomon B. Sirima0Alphonse Ouedraogo1Nouhoun Barry2Mohamadou Siribie3Alfred B. Tiono4Issa Nébié5Amadou T. Konaté6Gloria Damoaliga Berges7Amidou Diarra8Moussa Ouedraogo9Issiaka Soulama10Alimatou Hema11Shrimati Datta12Yuanyuan Liang13Elizabeth T. Rotrosen14J. Kathleen Tracy15Leslie P. Jamka16Kathleen M. Neuzil17Matthew B. Laurens18Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso, West AfricaGroupe de Recherche Action en Santé, Ouagadougou, Burkina Faso, West AfricaGroupe de Recherche Action en Santé, Ouagadougou, Burkina Faso, West AfricaGroupe de Recherche Action en Santé, Ouagadougou, Burkina Faso, West AfricaGroupe de Recherche Action en Santé, Ouagadougou, Burkina Faso, West AfricaGroupe de Recherche Action en Santé, Ouagadougou, Burkina Faso, West AfricaGroupe de Recherche Action en Santé, Ouagadougou, Burkina Faso, West AfricaGroupe de Recherche Action en Santé, Ouagadougou, Burkina Faso, West AfricaGroupe de Recherche Action en Santé, Ouagadougou, Burkina Faso, West AfricaGroupe de Recherche Action en Santé, Ouagadougou, Burkina Faso, West AfricaGroupe de Recherche Action en Santé, Ouagadougou, Burkina Faso, West AfricaGroupe de Recherche Action en Santé, Ouagadougou, Burkina Faso, West AfricaCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA; Corresponding author at: Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W Baltimore St Room 480, Baltimore, MD, 21201, USA.Objectives: The World Health Organization pre-qualified single-dose typhoid conjugate vaccine (TCV) and requested data on co-administration with routine vaccines. The co-administration of Typbar TCV (Bharat Biotech International) with routine group A meningococcal conjugate vaccine (MCV-A) and measles–rubella (MR) vaccine was tested. Methods: This was a double-blind, randomized controlled trial performed in Ouagadougou, Burkina Faso. Children were recruited at the 15-month vaccination visit and were assigned randomly (1:1:1) to three groups. Group 1 children received TCV plus control vaccine (inactivated polio vaccine) and MCV-A 28 days later; group 2 children received TCV and MCV-A; group 3 children received MCV-A and control vaccine. Routine MR vaccine was administered to all participants. Safety was assessed at 0, 3, and 7 days after immunization, and unsolicited adverse events and serious adverse events were assessed for 28 days and 6 months after immunization, respectively. Results: A total of 150 children were recruited and vaccinated. Solicited symptoms were infrequent and similar for TCV and control recipients, as were adverse events (group 1, 61.2%; group 2, 64.0%; group 3, 68.6%) and serious adverse events (group 1, 2.0%; group 2, 8.0%; group 3, 5.9%). TCV generated robust immunity without interference with MCV-A vaccine. Conclusions: TCV can be safely co-administered at 15 months with MCV-A without interference. This novel study on the co-administration of TCV with MCV-A provides data to support large-scale uptake in sub-Saharan Africa.http://www.sciencedirect.com/science/article/pii/S1201971220323092Typhoid conjugate vaccineMeningococcal vaccinesMeasles–rubella vaccineCo-administrationSub-Saharan AfricaBurkina Faso |
| spellingShingle | Sodiomon B. Sirima Alphonse Ouedraogo Nouhoun Barry Mohamadou Siribie Alfred B. Tiono Issa Nébié Amadou T. Konaté Gloria Damoaliga Berges Amidou Diarra Moussa Ouedraogo Issiaka Soulama Alimatou Hema Shrimati Datta Yuanyuan Liang Elizabeth T. Rotrosen J. Kathleen Tracy Leslie P. Jamka Kathleen M. Neuzil Matthew B. Laurens Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso International Journal of Infectious Diseases Typhoid conjugate vaccine Meningococcal vaccines Measles–rubella vaccine Co-administration Sub-Saharan Africa Burkina Faso |
| title | Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso |
| title_full | Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso |
| title_fullStr | Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso |
| title_full_unstemmed | Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso |
| title_short | Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso |
| title_sort | safety and immunogenicity of co administration of meningococcal type a and measles rubella vaccines with typhoid conjugate vaccine in children aged 15 23 months in burkina faso |
| topic | Typhoid conjugate vaccine Meningococcal vaccines Measles–rubella vaccine Co-administration Sub-Saharan Africa Burkina Faso |
| url | http://www.sciencedirect.com/science/article/pii/S1201971220323092 |
| work_keys_str_mv | AT sodiomonbsirima safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT alphonseouedraogo safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT nouhounbarry safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT mohamadousiribie safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT alfredbtiono safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT issanebie safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT amadoutkonate safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT gloriadamoaligaberges safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT amidoudiarra safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT moussaouedraogo safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT issiakasoulama safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT alimatouhema safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT shrimatidatta safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT yuanyuanliang safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT elizabethtrotrosen safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT jkathleentracy safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT lesliepjamka safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT kathleenmneuzil safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso AT matthewblaurens safetyandimmunogenicityofcoadministrationofmeningococcaltypeaandmeaslesrubellavaccineswithtyphoidconjugatevaccineinchildrenaged1523monthsinburkinafaso |